Condition: Venous Thromboembolism · Metastatic Pancreatic Cancer · Locally Advanced Pancreatic Adenocarcinoma · Sponsor: Quercis Pharma AG
The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.
This description comes directly from the study's public registry record.
Mukesh Kumar, PhD · 240-750-4893 · mkumar@fdamap.com
Kanisha Shah, MSRA · kanishas@fdamap.com
Always discuss trial participation with your own doctor first.
| Ventura Clinical Trials | Ventura, California, United States | Recruiting |
| Clavis Medical, LLC | Miami Lakes, Florida, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06861088